Granted Patent
B2
US 12,263,207 · App. 17/196,858 · Granted Apr 1, 2025
Human alpha-galactosidase variants
Inventors:
Nicholas J. Agard (San Francisco, CA); Mathew G. Miller (San Carlos, CA); Xiyun Zhang (Fremont, CA); Gjalt W. Huisman (Redwood City, CA)
Assignee:
Crosswalk Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
Claims (33)
1. A recombinant alpha galactosidase A comprising an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 5, wherein the amino acid sequence comprises at least a substitution at amino acid position 392, wherein the substitution at amino acid position 392 is 392G, 392P, 392S, 392T, 392A, 392D, 392Q, 392E, 392K, 392L, 392F, 392C, 392V, 392W, or 392N, and wherein the amino acid positions are relative to SEQ ID NO: 5.
2. The recombinant alpha galactosidase A of claim 1 , wherein the substitution is 392N.
3. The recombinant alpha galactosidase A of claim 1 , wherein the substitution is 392S or 392T.
4. The recombinant alpha galactosidase A of claim 1 , wherein the substitution is 392F or 392W.
5. The recombinant alpha galactosidase A of claim 1 , wherein the substitution is 392A, 392L, 392V or 392C.
6. The recombinant alpha galactosidase A claim 1 , wherein the substitution is 392D or 392E.
7. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A is more stable at pH 7.4 than the alpha galactosidase A of SEQ ID NO: 5.
8. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A is more stable at pH 4.3 than the alpha galactosidase A of SEQ ID NO: 5.
9. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A is more stable to exposure to serum than the alpha galactosidase A of SEQ ID NO: 5.
10. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A is purified.
11. A recombinant polynucleotide comprising a polynucleotide sequence encoding at least a recombinant alpha galactosidase A of claim 1 .
12. The recombinant polynucleotide of claim 11 , wherein said polynucleotide sequence is codon-optimized.
13. A host cell comprising a recombinant polynucleotide of claim 11 .
14. The host cell of claim 13 , wherein said host cell is a bacterial or mammalian cell.
15. A pharmaceutical composition comprising a recombinant alpha-galactosidase of claim 1 .
16. The pharmaceutical composition of claim 15 , further comprising a pharmaceutically acceptable carrier and/or excipient.
17. The pharmaceutical composition of claim 15 , wherein said composition is suitable for parenteral injection or infusion to a human.
18. A method for treating Fabry disease in a subject, comprising administering to a subject having Fabry disease an effective amount of a recombinant alpha-galactosidase A, wherein the recombinant alpha galactosidase A comprises an amino acid sequence comprising at least 90%, sequence identity to SEQ ID NO: 5, wherein the amino acid sequence comprises at least a substitution at amino acid position 392, wherein the substitution at amino acid position 392 is 392G, 392P, 392S, 392T, 392A, 392D, 392Q, 392E, 392K, 392L, 392F, 392C, 392V, 392W, or 392N and wherein the amino acid positions are relative to SEQ ID NO: 5.
19. The method of claim 18 , wherein said symptoms of Fabry disease are ameliorated.
20. The method of claim 18 , wherein said subject is able to eat a diet that is less restricted in its fat content than diets required by subjects exhibiting the symptoms of Fabry disease.
21. The method of claim 18 , wherein said subject is an infant or child.
22. The method of claim 18 , wherein said subject is an adult or young adult.
23. The recombinant alpha galactosidase A of claim 1 , wherein the substitution is 392Q or 392K.
24. The recombinant alpha galactosidase A of claim 1 , wherein the substitution is 392G or 392P.
25. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 91% sequence identity to SEQ ID NO: 5.
26. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 92% sequence identity to SEQ ID NO: 5.
27. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 93% sequence identity to SEQ ID NO: 5.
28. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 94% sequence identity to SEQ ID NO: 5.
29. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 5.
30. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 96% sequence identity to SEQ ID NO: 5.
31. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 97% sequence identity to SEQ ID NO: 5.
32. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 98% sequence identity to SEQ ID NO: 5.
33. The recombinant alpha galactosidase A of claim 1 , comprising an amino acid sequence comprising at least 99% sequence identity to SEQ ID NO: 5.
Assignments (4)
RELEASE OF SECURITY INTEREST
Recorded Aug 21, 2024
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
To: CODEXIS, INC.
Reel/Frame 068361/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 16, 2024
From: CODEXIS, INC.
To: CROSSWALK THERAPEUTICS, INC.
Reel/Frame 068660/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 2, 2024
From: AGARD, NICHOLAS J.; MILLER, MATHEW G.; ZHANG, XIYUN; HUISMAN, GJALT W.
To: CODEXIS, INC.
Reel/Frame 068164/0481 →
SECURITY INTEREST
Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (5)
Continuation
15529383
Provisional Application
62216452
· Sep 10, 2015
Provisional Application
62095313
· Dec 22, 2014
References Cited (260)
US 5179023A
· Calhoun et al.
· 1993
[cited by applicant]
US 5356804A
· Desnick et al.
· 1994
[cited by applicant]
US 5605793A
· Stemmer
· 1997
[cited by applicant]
US 5811238A
· Stemmer et al.
· 1998
[cited by applicant]
US 5830721A
· Stemmer et al.
· 1998
[cited by applicant]
US 5834252A
· Stemmer et al.
· 1998
[cited by applicant]
US 5837458A
· Minshull et al.
· 1998
[cited by applicant]
US 5928905A
· Stemmer et al.
· 1999
[cited by applicant]
US 6066626A
· Yew et al.
· 2000
[cited by applicant]
US 6083725A
· Selden et al.
· 2000
[cited by applicant]
US 6096548A
· Stemmer
· 2000
[cited by applicant]
US 6117679A
· Stemmer
· 2000
[cited by applicant]
US 6132970A
· Stemmer
· 2000
[cited by applicant]
US 6165793A
· Stemmer
· 2000
[cited by applicant]
US 6180406B1
· Stemmer
· 2001
[cited by applicant]
US 6251674B1
· Tobin et al.
· 2001
[cited by applicant]
US 6277638B1
· Stemmer
· 2001
[cited by applicant]
US 6287861B1
· Stemmer et al.
· 2001
[cited by applicant]
US 6287862B1
· delCardayre et al.
· 2001
[cited by applicant]
US 6291242B1
· Stemmer
· 2001
[cited by applicant]
US 6297053B1
· Stemmer
· 2001
[cited by applicant]
US 6303344B1
· Patten et al.
· 2001
[cited by applicant]
US 6309883B1
· Minshull et al.
· 2001
[cited by applicant]
US 6319713B1
· Patten et al.
· 2001
[cited by applicant]
US 6319714B1
· Crameri et al.
· 2001
[cited by applicant]
US 6323030B1
· Stemmer
· 2001
[cited by applicant]
US 6326204B1
· delCardayre et al.
· 2001
[cited by applicant]
US 6335160B1
· Patten et al.
· 2002
[cited by applicant]
US 6335198B1
· delCardayre et al.
· 2002
[cited by applicant]
US 6344356B1
· Stemmer
· 2002
[cited by applicant]
US 6352859B1
· delCardayre et al.
· 2002
[cited by applicant]
US 6355484B1
· Patten et al.
· 2002
[cited by applicant]
US 6358740B1
· Patten et al.
· 2002
[cited by applicant]
US 6358742B1
· Stemmer
· 2002
[cited by applicant]
US 6365377B1
· Patten et al.
· 2002
[cited by applicant]
US 6365408B1
· Stemmer
· 2002
[cited by applicant]
US 6368861B1
· Crameri et al.
· 2002
[cited by applicant]
US 6372497B1
· Stemmer
· 2002
[cited by applicant]
US 6376246B1
· Crameri et al.
· 2002
[cited by applicant]
US 6379964B1
· delCardayre et al.
· 2002
[cited by applicant]
US 6387702B1
· Stemmer
· 2002
[cited by applicant]
US 6391552B2
· Stemmer
· 2002
[cited by applicant]
US 6391640B1
· Minshull et al.
· 2002
[cited by applicant]
US 6395547B1
· Stemmer
· 2002
[cited by applicant]
US 6406855B1
· Patten et al.
· 2002
[cited by applicant]
US 6406910B1
· Patten et al.
· 2002
[cited by applicant]
US 6413745B1
· Patten et al.
· 2002
[cited by applicant]
US 6413774B1
· Stemmer
· 2002
[cited by applicant]
US 6420175B1
· Stemmer
· 2002
[cited by applicant]
US 6423542B1
· Crameri et al.
· 2002
[cited by applicant]
US 6426224B1
· Crameri et al.
· 2002
[cited by applicant]
US 6436675B1
· Welch et al.
· 2002
[cited by applicant]
US 6444468B1
· Stemmer et al.
· 2002
[cited by applicant]
US 6455253B1
· Patten et al.
· 2002
[cited by applicant]
US 6479652B1
· Crameri et al.
· 2002
[cited by applicant]
US 6482647B1
· Stemmer
· 2002
[cited by applicant]
US 6489146B2
· Stemmer et al.
· 2002
[cited by applicant]
US 6506602B1
· Stemmer
· 2003
[cited by applicant]
US 6506603B1
· Stemmer
· 2003
[cited by applicant]
US 6519065B1
· Colbourne et al.
· 2003
[cited by applicant]
US 6521453B1
· Crameri et al.
· 2003
[cited by applicant]
US 6528311B1
· delCardayre et al.
· 2003
[cited by applicant]
US 6537746B2
· Arnold et al.
· 2003
[cited by applicant]
US 6573098B1
· Stemmer
· 2003
[cited by applicant]
US 6576467B1
· Stemmer
· 2003
[cited by applicant]
US 6579678B1
· Patten et al.
· 2003
[cited by applicant]
US 6586182B1
· Patten et al.
· 2003
[cited by applicant]
US 6602986B1
· Stemmer et al.
· 2003
[cited by applicant]
US 6613514B2
· Patten et al.
· 2003
[cited by applicant]
US 6653072B1
· Patten et al.
· 2003
[cited by applicant]
US 6716631B1
· delCardayre et al.
· 2004
[cited by applicant]
US 6846968B1
· Erwin et al.
· 2005
[cited by applicant]
US 6946296B2
· Patten et al.
· 2005
[cited by applicant]
US 6961664B2
· Selfinov et al.
· 2005
[cited by applicant]
US 6995017B1
· Stemmer
· 2006
[cited by applicant]
US 7024312B1
· Selfinov et al.
· 2006
[cited by applicant]
US 7058515B1
· Selfinov et al.
· 2006
[cited by applicant]
US 7105297B2
· Minshull et al.
· 2006
[cited by applicant]
US 7148054B2
· delCardayre et al.
· 2006
[cited by applicant]
US 7288375B2
· Stemmer et al.
· 2007
[cited by applicant]
US 7421347B2
· Selfinov et al.
· 2008
[cited by applicant]
US 7430477B2
· Selfinov et al.
· 2008
[cited by applicant]
US 7531341B1
· Vellard et al.
· 2009
[cited by applicant]
US 7534564B2
· Patten et al.
· 2009
[cited by applicant]
US 7534595B2
· Vellard et al.
· 2009
[cited by applicant]
US 7560263B2
· Kakkis et al.
· 2009
[cited by applicant]
US 7620500B2
· Mundorff et al.
· 2009
[cited by applicant]
US 7620502B2
· Selfinov et al.
· 2009
[cited by applicant]
US 7629170B2
· delCardayre et al.
· 2009
[cited by applicant]
US 7702464B1
· Emig et al.
· 2010
[cited by applicant]
US 7747391B2
· Gustafsson et al.
· 2010
[cited by applicant]
US 7747393B2
· Fox
· 2010
[cited by applicant]
US 7751986B2
· Gustafsson et al.
· 2010
[cited by applicant]
US 7776598B2
· Patten et al.
· 2010
[cited by applicant]
US 7783428B2
· Gustafsson et al.
· 2010
[cited by applicant]
US 7795030B2
· Minshull et al.
· 2010
[cited by applicant]
US 7833742B2
· Treco et al.
· 2010
[cited by applicant]
US 7853410B2
· Selfinov et al.
· 2010
[cited by applicant]
US 7868138B2
· Stemmer et al.
· 2011
[cited by applicant]
US 7873499B2
· Selfinov et al.
· 2011
[cited by applicant]
US 7904249B2
· Selfinov et al.
· 2011
[cited by applicant]
US 7910545B2
· Meeker
· 2011
[cited by examiner]
US 7957912B2
· Selfinov et al.
· 2011
[cited by applicant]
US 8383346B2
· Colbeck et al.
· 2013
[cited by applicant]
US 8504498B2
· Fox
· 2013
[cited by applicant]
US 8768871B2
· Fox
· 2014
[cited by applicant]
US 8849575B2
· Gustafsson et al.
· 2014
[cited by applicant]
US 8876066B1
· Richards
· 2014
[cited by applicant]
US 9308281B2
· Guild et al.
· 2016
[cited by applicant]
US 9593326B2
· Clark et al.
· 2017
[cited by applicant]
US 9909113B2
· Calhoun et al.
· 2018
[cited by applicant]
US 20080220990A1
· Fox
· 2008
[cited by applicant]
US 20090312196A1
· Colbeck et al.
· 2009
[cited by applicant]
US 20110280856A1
· Selden et al.
· 2011
[cited by applicant]
US 20130039898A1
· Okhamafe et al.
· 2013
[cited by applicant]
US 20150050658A1
· Cho
· 2015
[cited by applicant]
US 20150134315A1
· Sarmiento et al.
· 2015
[cited by applicant]
US 20170051267A1
· Calhoun
· 2017
[cited by applicant]
US 20170360900A1
· Agard et al.
· 2017
[cited by applicant]
US 20210269787A1
· Hallows et al.
· 2021
[cited by applicant]
JP 2001504324
· 2001
[cited by applicant]
JP 2013520986A
· 2013
[cited by applicant]
WO 9522625A1
· 1995
[cited by applicant]
WO 9600787A1
· 1996
[cited by applicant]
WO 970078A1
· 1997
[cited by applicant]
WO 9735966A1
· 1997
[cited by applicant]
WO 9811206A2
· 1998
[cited by applicant]
WO 9827230A1
· 1998
[cited by applicant]
WO 200042651A1
· 2000
[cited by applicant]
WO 200175767A2
· 2001
[cited by applicant]
WO 2009152336A1
· 2009
[cited by applicant]
WO 2010144103A1
· 2010
[cited by applicant]
WO 2011107990A1
· 2011
[cited by applicant]
WO 2012170930A9
· 2012
[cited by applicant]
WO 2013156552A1
· 2013
[cited by applicant]
WO 2016105889A1
· 2016
[cited by applicant]
WO 2018132471A1
· 2018
[cited by applicant]
WO 2019125059A1
· 2019
[cited by applicant]
WO 2020132252A2
· 2020
[cited by applicant]
WO 2021026447A1
· 2021
[cited by applicant]
WO 2021173928A2
· 2021
[cited by applicant]
WO 2024042485A1
· 2024
[cited by applicant]
Warren et al., UniProt Database, accession No. F715N7_CALJA, Jul. 2011.
[cited by examiner]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 [1990].
[cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 [1997].
[cited by applicant]
Beaucage, S.L., et al., “Deoxynucleoside phosphoamidites—A new class of key intermediates for deoxypolynucleotide synthesis,” Tetrahedron Letters, 22(20):1859-62 [1981].
[cited by applicant]
Black, M.E., et al., “Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy,” Proc Natl Acad Sci USA, 93:3525-3529 [1996].
[cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201 [1985].
[cited by applicant]
Caldwell, R.C., et al., “Mutagenic PCR,” PCR Methods Appl., 3:S136-S140 [1994].
[cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 [1986].
[cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 [1999].
[cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 [1998].
[cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling, ”Nat. Biotechnol., 14(3):315-319 [1996].
[cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15(5):436-438 [1997].
[cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 [1996].
[cited by applicant]
Guo, Z., et al., “3′-End-Forming Signals of Yeast mRNA,” Mol. Cell. Biol., 15(11):5983-5990 [1995].
[cited by applicant]
Henikoff, S., et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci., 89:10915-10919 [1992].
[cited by applicant]
Ikeda, K., et al., “Phenylalanine ammonia-lyase modified with polyethylene glycol: Potential therapeutic agent for phenylketonuria,” Amino Acids, 29:283-287 [2005].
[cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of
[cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 [1997].
[cited by applicant]
Matthes, H.W.D., et al., “Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale,” EMBO J., 3(4):801-05 [1984].
[cited by applicant]
McIlvaine, T.C., “A Buffer Solution for Colorimetric Comparison,” J. Biol. Chem., 49:183-186 [1921].
[cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 [1999].
[cited by applicant]
Nance, C.S., et al., “Later-Onset Fabry Disease; An Adult Variant Presenting With the Cramp-Fasciculation Syndrome,” Arch. Neurol., 63:453-457 [2006].
[cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 [1970].
[cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 [1988].
[cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992].
[cited by applicant]
Schiffmann, R., “Fabry disease,” Pharm. Ther., 122:65-77 [2009].
[cited by applicant]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 [1985].
[cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 [1981].
[cited by applicant]
Southwood, S., et al., “Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires,” J. Immunol., 160:3363-3373 [1998].
[cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 [1994].
[cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 [1994].
[cited by applicant]
Vita, R., et al., “The Immune Epitope Database 2.0,” Nucl. Acids Res., 38(Database issue):D854-62 [2010].
[cited by applicant]
Wang, R.Y., et al., “Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals, ” Genet. Med., 13:457-484 [2011].
[cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 [1985].
[cited by applicant]
Yasuda, K., et al., “Efficient and rapid purification of recombinant human α-galactosidase A by affinity column chromatography,” Prot. Exp. Pur,. 37(2):499-506 [2004].
[cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening ,” Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 [1997].
[cited by applicant]
Zhao, H., et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol., 16:258-261 [1998].
[cited by applicant]
UniProt Database Accession No. F1PFDO dated May 3, 2011.
[cited by applicant]
UniProt Database Accession No. J3S8S8 dated Oct. 31, 2012.
[cited by applicant]
UniProt Database Accession No. G1LPQ5 dated Oct. 19, 2011.
[cited by applicant]
Guce, A.I., et al., “Catalytic Mechanism of Human Alpha-Galactosidase”, J. Biological Chemistry, 285(6):3625-3634 [2010].
[cited by applicant]
GenBank Assession No. AAP36507.1 dated May 13, 2003.
[cited by applicant]
Provencal, P., et al., “Relative distribution of Gb3 isoforms/analogsin NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry,” Bioanal., 8(17):1793-1807 [2016].
[cited by applicant]
GenBank Accession No. AAP36507.1.
[cited by applicant]
GenBank Accession No. BAD96347.
[cited by applicant]
Ogawa et al., “Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period”, Molecular Genetics and Metabolism, Academic Press, Amsterd…
[cited by applicant]
Advisory Action for U.S. Appl. No. 15/529,383, mailed on Jul. 30, 2020.
[cited by applicant]
Aurajsubebm A. et al., “Modified base compositions at the degenerate positions of a mutagenic oligonucleotide enhance randomness in site-saturation mutagenesis,” Nucleic Acids Res., vol. 26; 576-581 (1998).
[cited by applicant]
Durant, B., “Sex differences of urinary and kidneyglobolriaosylceramide and Iyso-globolriaosylceramide in rabry mice”, J_ Lipid Res., 52:1742-6 [2011].
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/814,371, mailed on Feb. 20, 2024.
[cited by applicant]
Final Office Action for U.S. Appl. No. 15/529,383, mailed on May 18, 2020.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/985,761, mailed on Apr. 7, 2021.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/985,788, mailed on Feb. 14, 2022.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/186,462, mailed on Jan. 8, 2024.
[cited by applicant]
Goswami et al., “Gene Therapy Leaves a Vicious Cycle”, Front. One. 9:297, 2019, 25 pages (Year: 2019).
[cited by applicant]
Hideyuki Kobayashi, Koibuchi Research Report, vol. 29, pp. 3-12 (2013). Concise explanation met by submission of attached English translation of Japanese Office Action for Japanese Application No. 2022-078184, mailed Ju…
[cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US15/63329, mailed on Jul. 6, 2017.
[cited by applicant]
International Preliminary Report on Patent ability for PCT Patent Application No. PCT/US19/67493, mailed on Jul. 1, 2021.
[cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US21/19811, mailed on Sep. 9, 2022, 7 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US15/63329, mailed on Jun. 3, 2016, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US19/67493, mailed on Jun. 5, 2020, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/19811, mailed on Aug. 17, 2021, 10 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US15/63329, mailed on Mar. 22, 2016, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US19/67493, mailed on Mar. 19, 2020, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US21/19811, mailed on Jun. 24, 2021, 2 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/814,371, mailed on Jun. 28, 2023.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/985,742, mailed Sep. 2, 2020.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/529,383, mailed on Oct. 21, 2019.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/721,102, mailed on Nov. 5, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/985,761, mailed on Sep. 8, 2020.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/985,788, mailed on Oct. 21, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/186,462, mailed on Jan. 30, 2023.
[cited by applicant]
Notice for Allowance for U.S. Appl. No. 17/186,462, mailed on Jul. 8, 2024.
[cited by applicant]
Notice of Allowability for U.S. Appl. No. 16/985,742, mailed Mar. 16, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/814,371, mailed on Jun. 12, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/814,371, mailed on May 7, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/721,102, mailed on Apr. 22, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,742, mailed Dec. 7, 2020.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,761, mailed on Aug. 4, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,761, mailed on Nov. 23, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,788, mailed on Jul. 8, 2022.
[cited by applicant]
Notice of File Missing Part for U.S. Appl. No. 18/656,340, mailed May 23, 2024.
[cited by applicant]
Qui, H., et al., “Impact of cysteine variants on the structure, activity, and stability of recombinant human alpha-galactosidase A,” The Protein Society, 24(9)1401-1411 [2015].
[cited by applicant]
Schultz, S.C. et al., “Site Saturation Mutagenesis of Active Site Residues of β-Lactamase,” Proteins Structure and Function, pp. 521-528, Plenum Press, New York (1987).
[cited by applicant]
Siekierska, A. et al., “a-Galactosidase Aggregation is a Determinant of Pharmacological Chaperone Efficacy in Fabry Disease Mutants,” J. Biol. Chem., vol. 287; 28386-28397 (2012).
[cited by applicant]
Singh et al., Curr. Protein Pept. Sci. 18:1-11, 2017 (Year: 2017).
[cited by applicant]
Sugawara, K., et al., “Structural characterization of mutant alpha-galactosidases causing Fabry disease,” J. Hum. Genet., 53(9):812-824 [2008].
[cited by applicant]
Uniprot Accession P06280. Alpha galactosidase A, Dec. 5, 2018.
[cited by applicant]
Uniprot Database Accession No. A0A6PSICW3, Jun. 2021, 2 pages (Year: 2021).
[cited by applicant]
UniProt Database Accession No. A0A6P6IS94, Jun. 2021, 2 pages (Year: 2021).
[cited by applicant]
Uniprot Database Accession No. D5FGE4, Aug. 2017, 2 pages (Year: 2017).
[cited by applicant]
UniProt Database Accession No. F7BKN6, Aug. 2017, 2 pages (Year: 2017).
[cited by applicant]
Vita, R., et al., “The Immune Epitope Database 2.0,” Nucl. Acids Res., 38(Database issue):0854-62 [2010].
[cited by applicant]
Yoshikatsu Eto, Journal of the Japanese Society of Internal Medicine, vol. 98, No. 4, pp. 163-170 (2009). Concise explaination met by submission of attached English translation of Japanese Office Action for Japanese App…
[cited by applicant]
Yoshitmitsu, M. et al. “Sequencing and characterization of the porcine a-galactosidase A gene: towards the generation of a procine model for Fabry diease,” Mo. Biol. Rep., vol. 38; 3145-3152 (2011).
[cited by applicant]
Zhang et al., Structure 26:1474-1485, 2018 (Year: 2018).
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/814,371, mailed Dec. 30, 2024.
[cited by applicant]